BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly’s Leukemia Drug Jaypirca Shows Promise in Late-Stage Trial
Eli Lilly’s Leukemia Drug Jaypirca Shows Promise in Late-Stage Trial
7
3
BTCCSquare news:
Eli Lilly's blood cancer treatment Jaypirca (pirtobrutinib) demonstrated significant efficacy in a late-stage clinical trial for chronic lymphocytic leukemia (CLL/SLL). Patients treated with the therapy showed prolonged progression-free survival compared to standard chemotherapy.
The FDA-approved drug, currently indicated for patients with prior treatment failures, may see expanded use if these results hold. Small lymphocytic lymphoma—a condition marked by dysfunctional WHITE blood cell proliferation—carries high mortality in advanced stages.
This development strengthens Eli Lilly's oncology pipeline as the company pursues additional applications for the therapy. No immediate cryptocurrency market correlation was identified.
By:
